Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal

(By Adam Feurerstein and Matthew Herper for STAT)

In a blockbuster deal between two of biopharma’s largest players, Bristol-Myers Squibb said Thursday it plans to buy Celgene for $74 billion.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or


Leave a Reply